Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Vyne Therapeutics Inc
VYNECurrent price
1.25 USD
-0.01 USD (-0.79%)
Last closed
1.26 USD
Company
www.vynetherapeutics.com
ISIN
US92941V2097
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
20 837 564 USD
Yield for 12 month
-53.70 %
1Y
3Y
5Y
10Y
15Y
VYNE
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Address: 685 Route 202/206 N, Bridgewater, NJ, United States, 08807
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6.38 USDP/E ratio
–Dividend Yield
–Current Year
+501 000 USD
Last Year
+424 000 USD
Current Quarter
+84 000 USD
Last Quarter
+121 000 USD
Current Year
+497 000 USD
Last Year
+424 000 USD
Current Quarter
+80 000 USD
Last Quarter
+121 000 USD
Key Figures VYNE
1 year
3 years
5 years
10 years
EBITDA
-43 633 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-33.14 %
PEG Ratio
–
Return On Equity TTM
-56.54 %
Wall Street Target Price
6.38 USD
Revenue TTM
501 000 USD
Book Value
3.51 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
10.50 %
Dividend Yield
–
Gross Profit TTM
501 000 USD
Earnings per share
-0.93 USD
Diluted Eps TTM
-0.93 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics VYNE
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History VYNE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:18
Payout Ratio TTM
–
Last Split Date
13.02.2023
Stock Valuation VYNE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
10.04
Price Sales TTM
41.59
Enterprise Value EBITDA
1.84
Price Book MRQ
0.40
Financials VYNE
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators VYNE
For 52 weeks
1.26 USD
4.30 USD
50 Day MA
1.86 USD
Shares Short Prior Month
135 679
200 Day MA
2.26 USD
Short Ratio
0.91
Shares Short
191 069
Short Percent
1.27 %
BeatStart